Dr Reddys plans to launch value-added drugs in US as part of diversification, market entry strategy Medical Dialogues Bureau8 July 2019 1:32 PM ISTAs part of the diversification and new market entry strategy, DRL (Dr Reddys) plans to re-focus some of its Research and Development resources to...
Glenmark expects generics to drive growth over next 3 yrs Ruby Khatun Khatun25 Sept 2017 10:37 AM ISTMumbai: Pharma firm Glenmark Pharmaceuticals has said its pipeline of specialty and innovative products over the next three to four years is expected...